Based on filed results, annual revenue was KRW 14.1 billion in 2022, KRW 14.3 billion in 2023 (up 1.5% year on year), KRW 27.7 billion in 2024 (up 94.1%), and KRW 24.6 billion in 2025 (down 11.4%). 2024 was the largest year in the 2022 to 2025 period and 2022 the smallest.
The 2024 jump reflected KRW 7.1 billion of licensing royalty income, which fell to zero in 2025 and weighed on revenue. Press reports cite the company attributing the 2025 decline to lower CDMO and consumer sales.
Operating loss was KRW 57.5 billion in 2022, KRW 55.1 billion in 2023, KRW 24.2 billion in 2024, and KRW 29.2 billion in 2025. The operating margin moved from -408.3% in 2022 to -87.2% in 2024 and then deteriorated to -118.9% in 2025.
The company explained the 2025 widening as a base effect from one-off revenue booked on a licensing agreement in the prior year.
Net loss attributable to controlling shareholders narrowed from KRW 51.8 billion in 2022 to KRW 6.43 billion in 2025, while the net loss including non-controlling interests was KRW 7.69 billion in 2025.
The debt ratio fell from 48.7% in 2024 to 26.6% in 2025, and operating cash flow was negative in every year from 2022 to 2025, at -KRW 18.4 billion in 2025.
On a quarterly basis, the company posted a controlling-shareholder net profit of KRW 14.6 billion in Q4 2025 after turning positive, but then recorded net losses of KRW 6.35 billion in Q1 2026, KRW 42.1 billion in Q2 2026 and KRW 8.2 billion in Q3 2026.
Operating losses over the same quarters were KRW 6.1 billion, KRW 7.97 billion and KRW 7.45 billion, so the Q2 2026 net loss deserves a separate reading from operating performance. The combined controlling-shareholder net loss for the last four quarters is KRW 42 billion.